Yongtai Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongtai Liu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Jinzhi Lai
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
6 shared publicationsHui Wang
Department of Cardiology
4 shared publicationsJiuliang Zhao
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Shuaifuyuan, Beijing, China
4 shared publicationsMengtao Li
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Shuaifuyuan, Beijing, China
4 shared publicationsQian Wang
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Shuaifuyuan, Beijing, China
4 shared publicationsXiaofeng Zeng
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Shuaifuyuan, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Springer Nature in Echo Research & Practice
- Vol. 13 (1) , 6
The diagnostic value of left atrial stiffness for heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation
Aims: Left atrial (LA) function is impaired in both atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Diagnosing HFpEF remains challenging, especially in AF patients. This study aims to evaluate whether LA stiffness (LAS) can facilitate the diagnosis of HFpEF in patients with paroxysmal atrial fibrillation (pxAF). Methods and results: A total of 187 pxAF patients were enrolled in the discovery cohort and underwent baseline transthoracic echocardiography (TTE). LAS was measured in all patients, and HFpEF was ascertained based on the H 2 FPEF score (44 high-probability of HFpEF [hp-HFpEF], 143 low-probability of HFpEF [lp-HFpEF]). The left ventricular diastolic function and LA function were significantly altered in the hp-HFpEF group compared to the lp-HFpEF group. Among all echocardiographic indices, the ratio of E/MVE’ to 3D LAEF as a surrogate of LAS showed the greatest diagnostic performance in distinguishing hp-HFpEF from lp-HFpEF in pxAF patients (AUC = 0.862, 95% CI 0.801–0.922, p < 0.001), with an optimal cutoff value of 0.27. Combining MVE’ and LAS revealed the highest diagnostic efficiency (LR + 12.18) compared to any single variable. The discriminatory value of LAS with MVE’ was further verified in the validation cohort with an LR + of 7.18. Conclusion: LAS analyzed by conventional echocardiography combined with MVE’ is a non-invasive, decision-support approach for discriminating hp-HFpEF from lp-HFpEF in pxAF patients. The clinical trial registration number: ClinicalTrials.gov NCT05266144.
- 23 February 2026
- Published by Springer Nature in Echo Research & Practice
- Vol. 13 (1) , 6
Open AccessThe diagnostic value of left atrial stiffness for heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation
Aims: Left atrial (LA) function is impaired in both atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Diagnosing HFpEF remains challenging, especially in AF patients. This study aims to evaluate whether LA stiffness (LAS) can facilitate the diagnosis of HFpEF in patients with paroxysmal atrial fibrillation (pxAF). Methods and results: A total of 187 pxAF patients were enrolled in the discovery cohort and underwent baseline transthoracic echocardiography (TTE). LAS was measured in all patients, and HFpEF was ascertained based on the H 2 FPEF score (44 high-probability of HFpEF [hp-HFpEF], 143 low-probability of HFpEF [lp-HFpEF]). The left ventricular diastolic function and LA function were significantly altered in the hp-HFpEF group compared to the lp-HFpEF group. Among all echocardiographic indices, the ratio of E/MVE’ to 3D LAEF as a surrogate of LAS showed the greatest diagnostic performance in distinguishing hp-HFpEF from lp-HFpEF in pxAF patients (AUC = 0.862, 95% CI 0.801–0.922, p < 0.001), with an optimal cutoff value of 0.27. Combining MVE’ and LAS revealed the highest diagnostic efficiency (LR + 12.18) compared to any single variable. The discriminatory value of LAS with MVE’ was further verified in the validation cohort with an LR + of 7.18. Conclusion: LAS analyzed by conventional echocardiography combined with MVE’ is a non-invasive, decision-support approach for discriminating hp-HFpEF from lp-HFpEF in pxAF patients. The clinical trial registration number: ClinicalTrials.gov NCT05266144.
- Open Access
- 15 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (1)
Isolated Right Ventricular Hypertrophic Cardiomyopathy Mimicking an Intramural Mass in a 13‐Year‐Old Male
Hypertrophic cardiomyopathy (HCM) primarily involves the left ventricle, with severe right ventricular hypertrophy or right ventricular outflow tract (RVOT) obstruction being rare. Hypertrophic myocardium may mimic intramural masses, requiring imaging, intraoperative observation and pathological examination for diagnosis. Here, we present a case of RVOT‐type HCM.
- 15 January 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (1)
Open AccessIsolated Right Ventricular Hypertrophic Cardiomyopathy Mimicking an Intramural Mass in a 13‐Year‐Old Male
Hypertrophic cardiomyopathy (HCM) primarily involves the left ventricle, with severe right ventricular hypertrophy or right ventricular outflow tract (RVOT) obstruction being rare. Hypertrophic myocardium may mimic intramural masses, requiring imaging, intraoperative observation and pathological examination for diagnosis. Here, we present a case of RVOT‐type HCM.
- Open Access
- 12 May 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1573539
Case Report: a 28-year-old female with anomalous origin of the left coronary artery from the pulmonary artery syndrome presented as atrial fibrillation and pulmonary hypertension
Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) typically manifests in the first weeks of life. We report a 28-year-old woman with atrial fibrillation and pulmonary hypertension which were later found to be associated with ALCAPA syndrome. Despite a history free of traditional cardiovascular risk factors, her symptoms included exercise intolerance, palpitations, and an ischemic stroke. Echocardiography and further examination revealed pulmonary artery origin of the left coronary artery and extensive collateral formation between the left and right coronary arteries, contributing to her symptoms.
- 12 May 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1573539
Open AccessCase Report: a 28-year-old female with anomalous origin of the left coronary artery from the pulmonary artery syndrome presented as atrial fibrillation and pulmonary hypertension
Anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) typically manifests in the first weeks of life. We report a 28-year-old woman with atrial fibrillation and pulmonary hypertension which were later found to be associated with ALCAPA syndrome. Despite a history free of traditional cardiovascular risk factors, her symptoms included exercise intolerance, palpitations, and an ischemic stroke. Echocardiography and further examination revealed pulmonary artery origin of the left coronary artery and extensive collateral formation between the left and right coronary arteries, contributing to her symptoms.
- Open Access
- 20 March 2025
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 43 (6) , 1042-1048
Predictive value of pulmonary to systemic vascular resistance ratio in systemic lupus erythematosus patients with pulmonary arterial hypertension
Objective: Pulmonary arterial hypertension (PAH) is a serious complication of systemic lupus erythematosus (SLE) with high mortality. The ratio of pulmonary to systemic vascular resistance (SVR) (Rp : Rs) may increase with disease progression. However, the prognostic value of Rp : Rs in predicting the outcomes of patients with SLE-PAH remains to be elucidated. Methods: Between 1 February 2012, and 30 June 2022, consecutive patients with a diagnosis of SLE-PAH and minimum one follow-up were enrolled prospectively. The end points were all-cause mortality and lung transplantation. The predictive values of baseline clinical characteristics and hemodynamic parameters, including Rp : Rs, were analyzed using Cox proportional hazard analyses. C-statistics were used to compare the predictive ability between the models. Results: A total of 285 patients were included and followed up for a median duration of 3.41 (interquartile range 1.81–5.72), during which 58 (20.4%) patients reached the endpoint. Multivariable Cox regression analysis revealed that in addition to the 6-minute walk distance (6MWD), the Rp : Rs was an independent predictor of the endpoint [hazard ratio 24.72; 95% confidence interval (CI) 5.59–109.29, P < 0.001] in predicting the endpoint. The concordance index for a model incorporating the Rp : Rs and the 6MWD yielded a value of 0.75 (95% CI 0.68–0.82), which showed better predictive accuracy than the simplified risk stratification strategy. Introducing the Rp : Rs ratio to the 2022 ESC/ERS four-stratum model significantly improved its predictive performance for these patients. Conclusion: The Rp : Rs serves as an independent predictor of adverse prognosis in patients with SLE-PAH and could provide additional value over current risk-assessment tools.
- 20 March 2025
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 43 (6) , 1042-1048
Open AccessPredictive value of pulmonary to systemic vascular resistance ratio in systemic lupus erythematosus patients with pulmonary arterial hypertension
Objective: Pulmonary arterial hypertension (PAH) is a serious complication of systemic lupus erythematosus (SLE) with high mortality. The ratio of pulmonary to systemic vascular resistance (SVR) (Rp : Rs) may increase with disease progression. However, the prognostic value of Rp : Rs in predicting the outcomes of patients with SLE-PAH remains to be elucidated. Methods: Between 1 February 2012, and 30 June 2022, consecutive patients with a diagnosis of SLE-PAH and minimum one follow-up were enrolled prospectively. The end points were all-cause mortality and lung transplantation. The predictive values of baseline clinical characteristics and hemodynamic parameters, including Rp : Rs, were analyzed using Cox proportional hazard analyses. C-statistics were used to compare the predictive ability between the models. Results: A total of 285 patients were included and followed up for a median duration of 3.41 (interquartile range 1.81–5.72), during which 58 (20.4%) patients reached the endpoint. Multivariable Cox regression analysis revealed that in addition to the 6-minute walk distance (6MWD), the Rp : Rs was an independent predictor of the endpoint [hazard ratio 24.72; 95% confidence interval (CI) 5.59–109.29, P < 0.001] in predicting the endpoint. The concordance index for a model incorporating the Rp : Rs and the 6MWD yielded a value of 0.75 (95% CI 0.68–0.82), which showed better predictive accuracy than the simplified risk stratification strategy. Introducing the Rp : Rs ratio to the 2022 ESC/ERS four-stratum model significantly improved its predictive performance for these patients. Conclusion: The Rp : Rs serves as an independent predictor of adverse prognosis in patients with SLE-PAH and could provide additional value over current risk-assessment tools.
- 1 March 2025
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (4) , 721-732
HFpEF correlated with better improvement of left atrial function in post-ablation patients with paroxysmal atrial fibrillation
The extent of improvement in left atrial (LA) function after radiofrequency catheter ablation (RFCA) in patients with paroxysmal atrial fibrillation (PxAF) and its association with heart failure with preserved ejection fraction (HFpEF) remain unclear. This study aims to explore whether there is a difference in the improvement of LA function after RFCA in patients with PxAF combined with HFpEF compared to those without HFpEF. Patients with PxAF receiving RFCA were enrolled. LA volume index (LAVI), LA emptying fraction (LAEF), and LA peak reservoir strain (LA RS) were assessed using echocardiography at baseline and three months after RFCA. Changes in these parameters were compared between patients with a high probability of HFpEF (hp-HFpEF) and those with a medium or low probability of HFpEF (lp-HFpEF), as determined by the H2FPEF score. A total of 147 patients (mean age 62.6 years; 63.3% males) were recruited (hp-HFpEF = 30). Baseline LA function differed significantly between patients with hp-HFpEF and those with lp-HFpEF. Differences included LAVI, LAEF, and LA RS (all P < 0.01). The improvement in LA function 3 months after RFCA was significantly different between the two groups, even after adjusting for confounding factors. Specifically, patients with hp-HFpEF experienced greater reductions in LAVI, more improvement in LAEF, and greater improvement in LA RS compared to patients with lp-HFpEF. A high probability of HFpEF was correlated with greater improvement in LA function following RFCA in patients with PxAF. The clinical trial registration number: ClinicalTrials.gov NCT05266144.
- 1 March 2025
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (4) , 721-732
HFpEF correlated with better improvement of left atrial function in post-ablation patients with paroxysmal atrial fibrillation
The extent of improvement in left atrial (LA) function after radiofrequency catheter ablation (RFCA) in patients with paroxysmal atrial fibrillation (PxAF) and its association with heart failure with preserved ejection fraction (HFpEF) remain unclear. This study aims to explore whether there is a difference in the improvement of LA function after RFCA in patients with PxAF combined with HFpEF compared to those without HFpEF. Patients with PxAF receiving RFCA were enrolled. LA volume index (LAVI), LA emptying fraction (LAEF), and LA peak reservoir strain (LA RS) were assessed using echocardiography at baseline and three months after RFCA. Changes in these parameters were compared between patients with a high probability of HFpEF (hp-HFpEF) and those with a medium or low probability of HFpEF (lp-HFpEF), as determined by the H2FPEF score. A total of 147 patients (mean age 62.6 years; 63.3% males) were recruited (hp-HFpEF = 30). Baseline LA function differed significantly between patients with hp-HFpEF and those with lp-HFpEF. Differences included LAVI, LAEF, and LA RS (all P < 0.01). The improvement in LA function 3 months after RFCA was significantly different between the two groups, even after adjusting for confounding factors. Specifically, patients with hp-HFpEF experienced greater reductions in LAVI, more improvement in LAEF, and greater improvement in LA RS compared to patients with lp-HFpEF. A high probability of HFpEF was correlated with greater improvement in LA function following RFCA in patients with PxAF. The clinical trial registration number: ClinicalTrials.gov NCT05266144.
- Open Access
- 16 May 2022
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 66, 19-25
Relationship between the distribution of left atrial low-voltage zones and post-ablation atrial arrhythmia recurrence in patients with atrial fibrillation
- 16 May 2022
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 66, 19-25
Open AccessRelationship between the distribution of left atrial low-voltage zones and post-ablation atrial arrhythmia recurrence in patients with atrial fibrillation
- Open Access
- 11 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 872795
Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). PAH has high mortality, and risk assessment is critical for proper management. Whether the right ventricle to pulmonary artery (RV-PA) coupling accurately assesses risk status and predicts prognosis in patients with SSc-associated PAH has not been investigated.Methods: Between March 2010 and July 2018, 60 consecutive patients with SSc-associated PAH diagnosed by right heart catheterization were enrolled prospectively, and the mean follow-up period was 52.9 ± 27.0 months. The RV-PA coupling was assessed by the ratio of tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP) which was obtained by transthoracic echocardiography. The simplified risk stratification strategy was applied to assess the risk level of participants, and the endpoint was a composite of all-cause death and clinical worsening.Results: The receiver operating characteristic (ROC) curve of the ability to determine high-risk patients identified the optimal cut-off value of the TAPSE/PASP ratio as 0.194 mm/mmHg, and the ratio appeared to be a reliable indicator in the stratification of patients with high risk (area under the curve = 0.878, ROC P-value = 0.003), which showed the highest positive likelihood ratio (LR) (5.4) and the lowest negative LR (0) among a series of echocardiographic parameters. The TAPSE/PASP ratio was an independent predictive factor (HR = 0.01, 95% CI: 0.00–0.77, P = 0.037) for the composite endpoint, and patients with a TAPSE/PASP ratio >0.194 had a better overall survival for both the composite endpoint (log-rank χ2 = 5.961, P = 0.015) and all-cause mortality (log-rank χ2 = 8.004, P = 0.005) compared to the patients with a TAPSE/PASP ≤ 0.194.Conclusion: RV-PA coupling assessed by the TAPSE/PASP ratio provides added value as a straightforward and non-invasive approach for predicting risk stratification of patients with SSc-associated PAH. Meanwhile, a lower TAPSE/PASP ratio identified a subgroup with worse prognosis.
- 11 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 872795
Open AccessRight Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Background: Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). PAH has high mortality, and risk assessment is critical for proper management. Whether the right ventricle to pulmonary artery (RV-PA) coupling accurately assesses risk status and predicts prognosis in patients with SSc-associated PAH has not been investigated.Methods: Between March 2010 and July 2018, 60 consecutive patients with SSc-associated PAH diagnosed by right heart catheterization were enrolled prospectively, and the mean follow-up period was 52.9 ± 27.0 months. The RV-PA coupling was assessed by the ratio of tricuspid annular plane systolic excursion (TAPSE) and pulmonary artery systolic pressure (PASP) which was obtained by transthoracic echocardiography. The simplified risk stratification strategy was applied to assess the risk level of participants, and the endpoint was a composite of all-cause death and clinical worsening.Results: The receiver operating characteristic (ROC) curve of the ability to determine high-risk patients identified the optimal cut-off value of the TAPSE/PASP ratio as 0.194 mm/mmHg, and the ratio appeared to be a reliable indicator in the stratification of patients with high risk (area under the curve = 0.878, ROC P-value = 0.003), which showed the highest positive likelihood ratio (LR) (5.4) and the lowest negative LR (0) among a series of echocardiographic parameters. The TAPSE/PASP ratio was an independent predictive factor (HR = 0.01, 95% CI: 0.00–0.77, P = 0.037) for the composite endpoint, and patients with a TAPSE/PASP ratio >0.194 had a better overall survival for both the composite endpoint (log-rank χ2 = 5.961, P = 0.015) and all-cause mortality (log-rank χ2 = 8.004, P = 0.005) compared to the patients with a TAPSE/PASP ≤ 0.194.Conclusion: RV-PA coupling assessed by the TAPSE/PASP ratio provides added value as a straightforward and non-invasive approach for predicting risk stratification of patients with SSc-associated PAH. Meanwhile, a lower TAPSE/PASP ratio identified a subgroup with worse prognosis.
- 31 May 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (3) , 983-991
Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension
Objective: Pulmonary arterial hypertension (PAH) is a serious complication of SSc with high mortality. Interventricular systolic asynchrony (IVSA) is observed in PAH patients, but the effect of IVSA and its association with long-term mortality and clinical events in SSc-associated PAH are unclear. This study aimed to investigate the impact of IVSA on the prognosis of SSc-associated PAH. Methods: Between March 2010 and July 2018, a total of 60 consecutive patients with SSc-associated PAH were enrolled. The end point was a composite of all-cause mortality and clinical worsening. Asynchrony was assessed by colour-coded tissue Doppler imaging (TDI) echocardiography. The myocardial sustained systole curves (Sm) of the basal portion of the right ventricular (RV) free wall and left ventricular (LV) lateral wall were obtained. IVSA was defined as the time difference from the onset of the QRS complex to the end of Sm between LV and RV. Results: Patients with greater IVSA time differences presented with advanced pulmonary vascular resistance (PVR). The IVSA time difference was an independent predictive factor (Hazard Ratio (HR) = 1.018, 95% CI: 1.005, 1.031, P =0.005) for the composite end point and was significantly associated with PVR (r = 0.399, R2=0.092, P =0.002). Kaplan–Meier survival curves showed that patients with greater IVSA had worse prognoses (log-rank P =0.001). Conclusion: In conclusion, IVSA analysed by colour-coded TDI echocardiography provided added value as a noninvasive, easy-to-use approach for assessing the prognosis of patients with SSc-associated PAH. A significant IVSA time difference identifies the subgroup of patients at high risk of a poor prognosis.
- 31 May 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (3) , 983-991
Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension
Objective: Pulmonary arterial hypertension (PAH) is a serious complication of SSc with high mortality. Interventricular systolic asynchrony (IVSA) is observed in PAH patients, but the effect of IVSA and its association with long-term mortality and clinical events in SSc-associated PAH are unclear. This study aimed to investigate the impact of IVSA on the prognosis of SSc-associated PAH. Methods: Between March 2010 and July 2018, a total of 60 consecutive patients with SSc-associated PAH were enrolled. The end point was a composite of all-cause mortality and clinical worsening. Asynchrony was assessed by colour-coded tissue Doppler imaging (TDI) echocardiography. The myocardial sustained systole curves (Sm) of the basal portion of the right ventricular (RV) free wall and left ventricular (LV) lateral wall were obtained. IVSA was defined as the time difference from the onset of the QRS complex to the end of Sm between LV and RV. Results: Patients with greater IVSA time differences presented with advanced pulmonary vascular resistance (PVR). The IVSA time difference was an independent predictive factor (Hazard Ratio (HR) = 1.018, 95% CI: 1.005, 1.031, P =0.005) for the composite end point and was significantly associated with PVR (r = 0.399, R2=0.092, P =0.002). Kaplan–Meier survival curves showed that patients with greater IVSA had worse prognoses (log-rank P =0.001). Conclusion: In conclusion, IVSA analysed by colour-coded TDI echocardiography provided added value as a noninvasive, easy-to-use approach for assessing the prognosis of patients with SSc-associated PAH. A significant IVSA time difference identifies the subgroup of patients at high risk of a poor prognosis.
- Open Access
- 22 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors
Background: Cardiac manifestations are common and life-threatening in eosinophilic granulomatosis with polyangiitis (EGPA), which remains poorly studied in China. We aim to investigate its clinical features, associated factors, treatment, and outcomes. Methods: We reviewed the clinical records of 110 EGPA patients and examined the independent factors associated with cardiac manifestations using multivariate logistic regression. Receiver operating characteristic curves determined the cut-off values, and survival was calculated via Kaplan–Meier curves. Results: Cardiac involvement was present in 36.4% (40/110) of EGPA patients, which mainly manifested as pericardial effusion (16.4%, 18/110), myocardial involvement (13.6%, 15/110), and heart failure (8.2%, 9/110). The mean age was 42.1 ± 14.23 years with no female/male predominance. Compared with the cardiac-unaffected group, the cardiac-affected group showed a lower rate of biopsy-proved vasculitis (0% versus 20%, p = 0.002). The eosinophil count [odds ratio (OR) = 1.142, 95% confidence interval (CI) 1.029–1.267] was independently associated with cardiac manifestations in EGPA, with a cut-off value of 3.66 × 109/L [area under the curve (AUC) = 0.692, p = 0.001]. Regarding treatment, the cardiac-affected group displayed a higher ratio of glucocorticoid pulse combined with intravenous cyclophosphamide (CYC-IV) (40% versus 21.4%, p = 0.037), and intravenous immunoglobulin combined with glucocorticoid plus CYC-IV (17.5% versus 4.3%, p = 0.035) than the control group. Outcomes ( p = 0.131) and survival ( p = 0.1972) were not significantly different between the groups. Conclusion: In this single-center Chinese EGPA cohort, cardiac manifestations are observed in 36.4% of patients, which primarily presents as myocardial involvement, pericardial effusion, and heart failure, independently associated with eosinophil count. Glucocorticoid combined with cyclophosphamide is the treatment cornerstone for EGPA patients with cardiac manifestations.
- 22 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
Open AccessCardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors
Background: Cardiac manifestations are common and life-threatening in eosinophilic granulomatosis with polyangiitis (EGPA), which remains poorly studied in China. We aim to investigate its clinical features, associated factors, treatment, and outcomes. Methods: We reviewed the clinical records of 110 EGPA patients and examined the independent factors associated with cardiac manifestations using multivariate logistic regression. Receiver operating characteristic curves determined the cut-off values, and survival was calculated via Kaplan–Meier curves. Results: Cardiac involvement was present in 36.4% (40/110) of EGPA patients, which mainly manifested as pericardial effusion (16.4%, 18/110), myocardial involvement (13.6%, 15/110), and heart failure (8.2%, 9/110). The mean age was 42.1 ± 14.23 years with no female/male predominance. Compared with the cardiac-unaffected group, the cardiac-affected group showed a lower rate of biopsy-proved vasculitis (0% versus 20%, p = 0.002). The eosinophil count [odds ratio (OR) = 1.142, 95% confidence interval (CI) 1.029–1.267] was independently associated with cardiac manifestations in EGPA, with a cut-off value of 3.66 × 109/L [area under the curve (AUC) = 0.692, p = 0.001]. Regarding treatment, the cardiac-affected group displayed a higher ratio of glucocorticoid pulse combined with intravenous cyclophosphamide (CYC-IV) (40% versus 21.4%, p = 0.037), and intravenous immunoglobulin combined with glucocorticoid plus CYC-IV (17.5% versus 4.3%, p = 0.035) than the control group. Outcomes ( p = 0.131) and survival ( p = 0.1972) were not significantly different between the groups. Conclusion: In this single-center Chinese EGPA cohort, cardiac manifestations are observed in 36.4% of patients, which primarily presents as myocardial involvement, pericardial effusion, and heart failure, independently associated with eosinophil count. Glucocorticoid combined with cyclophosphamide is the treatment cornerstone for EGPA patients with cardiac manifestations.
- 1 November 2019
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 28 (11) , 1655-1663
Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension
- 1 November 2019
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 28 (11) , 1655-1663
Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension